Clinical Trial Update: Nivolumab for Recurrent or Progressive IDH Mutant Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab for recurrent or progressive IDH-mutant gliomas has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• Idh-mutant Glioma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Fabio Iwamoto, MD | Conditions: Gliomas | Phase 2 | Status: COMPLETED | Results posted: 2025-11-03